Desay Battery Unveils Innovative Energy Storage Solutions at SNEC PV+ Expo, Announces Strategic Partnership with Turkish Energy Leader Demir Enerji Français
"Through our partnership with Demir Enerji, we are excited to bring our most advanced energy storage technologies to Turkey's dynamic energy market," said Vice-President Jack Guo of Desay Battery. "This collaboration is a significant step in our global expansion strategy and highlights our dedication to advancing the transition to clean energy globally."
At the exhibition, Desay Battery showcased cutting-edge battery cell technology, featuring a diverse range of products. This lineup included high-performance lithium-ion cells (DLP-100, DLP-280, DLP-314) as well as the innovative DSP-60 sodium-ion battery. In addition to cell technology, Desay Battery unveiled its modular energy storage systems, which consist of scalable lithium modules at 100Ah and 280Ah, along with 52S battery packs that allow for flexible integration. For commercial and industrial applications, the company introduced the Lumos energy storage cabinets with capacities of 215kWh and 344kWh. For residential use, offerings included the 10-25kWh LV Residential ESS and the 21kWh HV DCDC Residential ESS (280Ah), designed to provide efficient and space-saving solutions for homes. Furthermore, Desay Battery exhibited large-scale infrastructure solutions, including the Vita 5MWh Utility ESS liquid-cooled container storage system, which supports grid stability, as well as UPS battery cabinets designed for critical backup power.
The products showcased not only highlight Desay Battery's leadership in energy storage technology but also demonstrate the company's deep understanding of diverse application needs, along with its ability to deliver precise, tailored solutions.
"With over 20 years of specialized experience, Desay Battery has firmly positioned itself as a Tier 1 energy storage provider, recently earning a spot on BloombergNEF's Energy Storage Tier 1 List for Q2 2025. This recognition underscores the company's vertically integrated approach, which covers the entire spectrum from cell development to complete system integration. Supported by state-of-the-art manufacturing facilities and rigorous quality control processes, Desay Battery continues to set the standard in the energy storage industry."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Market Online
2 days ago
- The Market Online
Pulsar Helium stock rises after tripling well flow rate
Pulsar Helium (TSXV:PLSR) has more than tripled 2024 natural flow test rates from the Jetstream #1 well at its Topaz project in Minnesota Besides Topaz, Pulsar is advancing the Tunu project in Greenland, with both projects featuring primary helium occurrences not associated with the production of hydrocarbons Pulsar Helium stock has given back 12.90 per cent year-over-year but remains up by 390.91 per cent since inception in 2023 Junior explorer Pulsar Helium (TSXV:PLSR) has more than tripled 2024 natural flow test rates from the Jetstream #1 well at its Topaz project in Minnesota. This content has been prepared as part of a partnership with Pulsar Helium Inc., and is intended for informational purposes only. On August 15, the well reached ~501,000 cubic feet per day (Mcf/d) on a 38/64' choke at ~30 pounds per square inch (psi) well head pressure (WHP) with no compression, stimulation or formation water. Jetstream #1 also posted long-duration flows of 150–300 Mcf/d for periods of 12–18 hours on smaller choke sizes, showing rapid pressure recovery and no significant decline. Results in April 2024 peaked at ~150 Mcf/d at 34 psi WHP (~821 Mcf/d under well-head compression) with helium concentrations ranging from 8.7 to 14.5 per cent, miles ahead of the 0.3 per cent economic threshold for the commodity. According to Monday's news release, the results support Topaz's potential as a top global helium resource, with the company vying to further substantiate this potential through sustained-flow testing, full gas composition analyses and flow testing under well-head compression (which is expected to significantly increase flow rates) over the near term. The company will then conduct the same testing regimen on Jetstream #2, which was completed on February 1st, reaching a depth of 1,728 metres. Leadership insights 'The deepening of the Jetstream #1 appraisal well to a total depth of 5,100 feet, penetrating the entire interpreted helium-bearing zone, has proven highly successful,' Thomas Abraham-James, Pulsar Helium's president and chief executive officer, said in a statement. 'The well is now naturally flowing at ~501,000 cubic feet per day at 30 pounds per square inch WHP, more than three times the peak natural flow achieved in 2024. This result validates our subsurface model, significantly de-risks the Topaz project and confirms the reservoir's outstanding productivity. This is especially exciting considering the 2024 gas analysis for the same well returned helium concentrations ranging from 8.7 to 14.5 per cent. With further flow testing, including under well-head compression, and gas composition analyses to follow, we look forward to sharing further updates and the results of Jetstream #2. These results underscore the immense opportunity at Topaz and signal the start of unlocking its full potential.' About Pulsar Helium Pulsar Helium is advancing its flagship Topaz project in Minnesota, USA, and the Tunu project in Greenland, both of which feature primary helium occurrences not associated with the production of hydrocarbons. Pulsar Helium stock (TSXV:PLSR) is up by 11.34 per cent trading at C$0.54 as of 9:33 am ET. The stock has given back 12.90 per cent year-over-year but remains up by 390.91 per cent since inception in 2023. Join the discussion: Find out what investors are saying about this junior helium stock on the Pulsar Helium Inc. Bullboard and make sure to explore the rest of Stockhouse's stock forums and message boards. Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
Cision Canada
2 days ago
- Cision Canada
Aon Announces Strategic Investment in eMed to Scale GLP-1 Population Health Platform
Strategic investment is accelerating the transformation of employer-focused obesity solutions to boost adherence, retention and deliver breakthrough health outcomes with cost savings DUBLIN, Aug. 18, 2025 /CNW/ -- Aon plc (NYSE: AON), a leading global professional services firm, today announced a strategic investment in eMed Population Health, Inc., an emerging leader in the delivery of GLP-1 programs. The partnership will enhance employer sponsored access to GLP-1 therapies and scale solutions for obesity. The investment follows the launch earlier this year of Aon's subsidized GLP-1 weight management benefit program for its U.S. workforce – developed by eMed – which has delivered strong adherence, high retention and sustainable results for the firm's colleagues. In the sixth months since Aon's program launched, more than 1,200 people have registered and the firm has seen an average of 22.4 pounds lost with a retention rate of 95 percent. With this investment, eMed will continue to increase distribution of its digital-first healthcare platform — which combines at-home diagnostics, proctor-led screenings, clinician-guided prescribing, and continuous adherence support—to reach more employers and patients. "As the leader of Aon's People Organization, I know how important it's been to include GLP-1 coverage as part of our own U.S. Total Rewards strategy," said Lisa Stevens, Chief Administrative Officer for Aon. "When you see the benefits it brings to people you work with every day, it really underscores how the decisions employers make today shape the future health and performance of our workforces and our businesses." Stevens added: "This strategic investment in eMed enables our firm to have an active role in offering a global solution that is focused on medication adherence that will be differentiated in the marketplace in helping employers reduce long-term health costs while improving the quality of life for their people. By aligning innovation with behavior change and accountability, together we can deliver sustainable results at scale." The collaboration marks a major milestone in eMed's mission to deliver effective and sustainable care through an integrated, data-driven experience, while expanding its provider network, behavioral health tools and market reach. "Today marks a game-changing partnership between Aon and eMed and is a win for both payers and participants," said Linda Yaccarino, CEO of eMed Population Health, Inc. "Our shared vision of market transformation is validated and accelerated by the investment from Aon. This strategic investment in eMed further enables our firm to play an active role in offering a differentiated global solution focused on medication adherence – helping employers reduce long-term health costs while improving quality of life for their people." Aon continues to build a complimentary suite of GLP-1 solutions, industry-leading experience and advisory capabilities for clients. In April, Aon unveiled findings from its multi-year analysis of U.S. commercial health claims data, which evidenced the transformative potential of GLP-1 medications in managing obesity and improving health outcomes. "The rise of GLP-1 medications and its cost has sparked significant strategic considerations from employers looking to address obesity and other chronic conditions," said Farheen Dam, Head of Health for North America at Aon. "We know that GLP-1s are not a one size fits all strategy. This is why data, modelling and strategic guidance from our clinical, actuarial and pharmacy teams help employers build GLP-1s strategies that fit their population and objectives." About eMed eMed® is the world's first end-to-end GLP-1 care platform built on Empathetic AI™. From remote diagnostics and clinician-led prescriptions to adherence coaching and insights, eMed empowers employers to manage population health with accountability and compassion. Learn more at About Aon Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses. Media Contacts eMed Matt Gorman [email protected] Aon [email protected] Toll-free (U.S., Canada and Puerto Rico): +1 833 751 8114 International: +1 312 381 3024 SOURCE Aon plc
Canada News.Net
5 days ago
- Canada News.Net
Texas AG Paxton files suit accusing Eli Lilly of illegal kickbacks
WASHINGTON, D.C.: Texas Attorney General Ken Paxton has filed a lawsuit against U.S. pharmaceutical giant Eli Lilly, alleging the company engaged in an illegal scheme to pay kickbacks to healthcare providers to encourage prescriptions of its most profitable medications. According to Paxton's office, the alleged scheme targeted drugs such as Mounjaro and Zepbound, GLP-1 medications used to treat diabetes and aid weight loss, with financial inducements designed to sway medical decision-making in the company's favor. "Big Pharma compromised medical decision-making by engaging in an illegal kickback scheme," Paxton said in a statement, adding that the case builds on previous efforts to hold drugmakers accountable for fraud and abuse. The lawsuit follows earlier legal action by Paxton's office against insulin manufacturers, including Lilly, and pharmacy benefit managers (PBMs). That case claimed manufacturers inflated insulin prices and then funneled a significant, undisclosed share back to PBMs in exchange for preferential placement on drug formularies. Eli Lilly denied wrongdoing, saying the new claims come from the same corporate whistleblower whose allegations have been dismissed by multiple courts and rejected by the federal government. "We intend to vigorously defend against these allegations," a company spokesperson said, citing prior rulings that found the accusations lacked factual and legal merit.
